VistaGen Therapeutics Q1 EPS $(0.47) Beats $(0.50) Estimate, Sales $244.00K Miss $650.00K Estimate
Benzinga·08/07/2025 20:51:27
Listen to the news
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.50) by 6 percent. This is a 34.29 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $244.00 thousand which missed the analyst consensus estimate of $650.00 thousand by 62.46 percent. This is a 190.48 percent increase over sales of $84.00 thousand the same period last year.
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.